Incidence of actionable findings on contrast enhanced magnetic resonance angiography ordered for pulmonary embolism evaluation.
To determine the incidence of actionable findings on contrast-enhanced magnetic resonance angiography (MRA) scans performed for the primary diagnosis of pulmonary embolism (PE). This was a HIPAA-compliant and IRB-approved single center, retrospective study of consecutive series of patients evaluated with contrast-enhanced MRA for PE. The final radiology report of each MRA was reviewed. All technically adequate negative exams were included in the analysis. The findings were divided into three types: those requiring further action (actionable-Type 1) those not requiring follow-up (non-actionable-Type 2) and normal exams. We compared our results with the literature regarding the use of computed tomographic angiography (CTA) in this scenario using Fisher's exact test. 580 MRA scans for PE were performed. There were 561/580 (97%) technically adequate exams. Of these, 514/580 (89%) were negative and 47/580 (8%) were positive for PE. In the PE negative group of 514 exams, Type 1 findings were identified in 85/514 (17%), 188/514 (36%) cases were Type 2 and 241/514 (47.0%) were Type 3. There was no significant difference between the incidence of Type 1 and the combination of Type 2 and Type 3 findings on MRA and the reported incidence of actionable findings derived from CTA negative exams for PE (p<0.5). MRA as a first-line test for PE can identify actionable findings in those patients without PE, with an incidence similar to that reported in the literature for CTA.